US Pharmaceutical Investment
Figures published in August 2026 indicate that global pharmaceutical companies invested approximately US$500 billion into the US pharmaceutical sector in 2026. This strategic move aims to enhance supply chain resilience and mitigate tariff impacts.
Notable investment commitments include the establishment of new manufacturing facilities:
- Bristol Myers Squibb announced a US$2.3 billion manufacturing campus in Houston, Texas, as part of a larger US$40 billion five-year commitment to US R&D, technology, and domestic manufacturing.
- Roche pledged US$50 billion in April 2025 for US pharmaceuticals and diagnostics over five years.
- Pfizer unveiled a landmark investment of US$70 billion in US research and development and domestic manufacturing in September 2025.
Other major companies, including Eli Lilly, Novo, Novartis, Johnson & Johnson, and GSK, have also made significant investment commitments.
Bayer – Key Partners
Google Cloud
- CEO: Thomas Kurian
- HQ: Mountain View, California
Bayer collaborates with Google Cloud on AI-powered healthcare applications, particularly in radiology. Their initiatives include Bayer’s AI Innovation Platform, leveraging Google Cloud technologies like Vertex AI and BigQuery to develop compliant medical imaging AI applications.
Huma
- CEO: Dan Vahdat
- HQ: London, UK
Bayer partners with Huma on digital cardiovascular health projects, including the Bayer Aspirin Heart Health Risk Assessment. Huma created the underlying algorithm using UK Biobank data to predict individual long-term cardiovascular disease risk. The partnership expanded to Saudi Arabia in 2024 as part of Bayer’s digital preventative health strategy.
Recursion
- CEO: Najat Khan
- HQ: Salt Lake City, Utah
Bayer collaborates with Recursion in AI-enabled drug discovery. This partnership aligns with Bayer’s objective of using data science and advanced technologies throughout the pharmaceutical value chain. Recursion merges automated lab experimentation with machine learning and large biological datasets to identify and develop new medications.
